Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Criteria:

* No prior bevacizumab
* Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)
* Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques or \>= 10 mm by spiral CT scan
* Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)
* Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin®) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)
* No known brain metastases
* ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%
* Life expectancy \> 12 weeks
* Absolute neutrophil count \>= 1,500/mm³
* Platelets \>=100,000/mm³
* Total bilirubin normal (exception made for patients with known Gilbert's disease)
* AST/ALT =\< 2.5 times upper limit of normal (ULN)
* No proteinuria \> +1 on two consecutive dipsticks taken \>= 1 week apart
* PT/INR/PTT =\< 1.2 times ULN
* No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents
* No QTc prolongation (defined as a QTc interval \>= 500 msecs) or other significant ECG abnormalities
* No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug
* No poorly controlled hypertension (systolic blood pressure \[BP\] \>= 140 mm Hg or diastolic BP \>= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is \< 140/90 mm Hg
* No serious or non-healing wound, ulcer, or bone fracture
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks
* No cerebrovascular accident within the last 6 months
* No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks
* No venous thrombosis within the last 12 weeks
* No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment
* No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery
* No cardiac angioplasty or stenting within the last 12 weeks
* No more than 1 prior chemotherapy regimen for recurrent disease
* No prior surgical procedures affecting absorption
* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:

Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed

* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:

  * Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil
  * Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine
  * Immune modulators: cyclosporine, tacrolimus, or sirolimus
  * Miscellaneous: theophylline, quetiapine, or risperidone
* No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:

  * Oral hypoglycemics: glipizide, glyburide, or tolbutamide
  * Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine
  * Neuroleptics: pimozide
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No other concurrent anticancer therapy
* WBC \>= 3,000/mm³
* No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease
* Creatinine normal OR creatinine clearance \>= 60 mL/min
* At least 3 months since prior trastuzumab